Venus Remedies Limited (VENUSREM) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.136x

Based on the latest financial reports, Venus Remedies Limited (VENUSREM) has a cash flow conversion efficiency ratio of 0.136x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs811.10 Million ≈ $8.77 Million USD) by net assets (Rs5.94 Billion ≈ $64.27 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Venus Remedies Limited - Cash Flow Conversion Efficiency Trend (2006–2025)

This chart illustrates how Venus Remedies Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read VENUSREM liabilities breakdown for a breakdown of total debt and financial obligations.

Venus Remedies Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Venus Remedies Limited ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Syrah Resources Ltd
AU:SYR
-0.089x
Heidelberg Pharma AG
F:HPHA
-0.299x
Multitude SE
LSE:0R4W
0.115x
UBcare. Co. Ltd
KQ:032620
0.016x
Laxmi Goldorna House Ltd
NSE:LGHL
-0.023x
USBC, Inc.
NYSE MKT:USBC
-0.032x
ANDREW PELLER LTD A
F:ANJ
0.013x
Samick Thk
KO:004380
0.064x

Annual Cash Flow Conversion Efficiency for Venus Remedies Limited (2006–2025)

The table below shows the annual cash flow conversion efficiency of Venus Remedies Limited from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see Venus Remedies Limited stock valuation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-03-31 Rs5.61 Billion
≈ $60.66 Million
Rs909.20 Million
≈ $9.83 Million
0.162x +111.94%
2024-03-31 Rs4.88 Billion
≈ $52.73 Million
Rs372.85 Million
≈ $4.03 Million
0.076x -3.87%
2023-03-31 Rs4.60 Billion
≈ $49.78 Million
Rs366.20 Million
≈ $3.96 Million
0.080x -14.55%
2022-03-31 Rs4.40 Billion
≈ $47.63 Million
Rs410.01 Million
≈ $4.43 Million
0.093x -71.90%
2021-03-31 Rs4.00 Billion
≈ $43.29 Million
Rs1.33 Billion
≈ $14.34 Million
0.331x +39.12%
2020-03-31 Rs3.23 Billion
≈ $34.97 Million
Rs770.10 Million
≈ $8.33 Million
0.238x +74.71%
2019-03-31 Rs3.33 Billion
≈ $35.96 Million
Rs453.27 Million
≈ $4.90 Million
0.136x -4.09%
2018-03-31 Rs3.62 Billion
≈ $39.14 Million
Rs514.36 Million
≈ $5.56 Million
0.142x -35.64%
2017-03-31 Rs4.52 Billion
≈ $48.84 Million
Rs997.24 Million
≈ $10.78 Million
0.221x +106.13%
2016-03-31 Rs4.38 Billion
≈ $47.33 Million
Rs468.81 Million
≈ $5.07 Million
0.107x -27.85%
2015-03-31 Rs4.57 Billion
≈ $49.39 Million
Rs678.05 Million
≈ $7.33 Million
0.148x +30.18%
2014-03-31 Rs4.62 Billion
≈ $49.92 Million
Rs526.46 Million
≈ $5.69 Million
0.114x -17.09%
2013-03-31 Rs3.79 Billion
≈ $41.00 Million
Rs521.50 Million
≈ $5.64 Million
0.138x +1.44%
2012-03-31 Rs3.07 Billion
≈ $33.23 Million
Rs416.70 Million
≈ $4.51 Million
0.136x -13.98%
2011-03-31 Rs2.37 Billion
≈ $25.62 Million
Rs373.47 Million
≈ $4.04 Million
0.158x -14.83%
2010-03-31 Rs1.71 Billion
≈ $18.51 Million
Rs316.83 Million
≈ $3.43 Million
0.185x +35.37%
2009-03-31 Rs1.39 Billion
≈ $14.99 Million
Rs189.50 Million
≈ $2.05 Million
0.137x -36.02%
2008-03-31 Rs889.86 Million
≈ $9.62 Million
Rs190.17 Million
≈ $2.06 Million
0.214x -50.89%
2007-03-31 Rs551.31 Million
≈ $5.96 Million
Rs239.88 Million
≈ $2.59 Million
0.435x +58.20%
2006-03-31 Rs318.96 Million
≈ $3.45 Million
Rs87.73 Million
≈ $948.76K
0.275x --

About Venus Remedies Limited

NSE:VENUSREM India Drug Manufacturers - Specialty & Generic
Market Cap
$139.85 Million
Rs12.93 Billion INR
Market Cap Rank
#17891 Global
#932 in India
Share Price
Rs967.40
Change (1 day)
+3.65%
52-Week Range
Rs299.20 - Rs1069.05
All Time High
Rs1069.05
About

Venus Remedies Limited engages in the pharmaceutical business in India and internationally. It is involved in the research and development of solutions focusing on antimicrobial resistance and oncology. The company also offers analgesic, analgesic and antipyretic, antibiotic, anticoagulant, antiemetic, antiviral, cardiovascular, disinfectant and antiseptic, gastro therapy, hepatoprotective, hormo… Read more